CHPG

• Description:

  CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways[2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  Akt; ERK; mGluR; NF-κB

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/chpg.html

• Purity:

  99.51

• Solubility:

  1M NaOH : 25 mg/mL (ultrasonic; adjust pH to 11 with NaOH) |DMSO : 25 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCl; heat to 60°C)

• Smiles:

  O=C(O)C(N)C1=CC(O)=CC=C1Cl

• Molecular Formula:

  C8H8ClNO3

• Molecular Weight:

  201.61

• Precautions:

  H302, H312, H332

• References & Citations:

  2

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  ERK; mGluR5; NF-κB

• Citation 01:

  IBRO Neurosci Rep. 2025 May 26:18:823-829.|World J Gastroenterol. 2025 Feb 21;31 (7) :98852. |Immunobiology. 2025 Jun 28;230 (4) :153095.|SSRN. 2025 Aug 27.

• CAS Number:

  [170846-74-9]